IBIO News

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Immorta Bio Demonstrates Dramatic Lifespan Extension in Aging Mouse Models; Research Accepted for Presentation at AAI's IMMUNOLOGY2026

Form 8-K

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

Form 8-K

SHINE Completes $240 Million in Recent Funding Led by Dr. Patrick Soon-Shiong, Founder of NantWorks, Who Joins Board of Directors

IntraBio Receives Positive European Medicines Agency Opinion for Orphan Medicinal Product Designation for Acetylleucine for CACNA1A Disorders

iBio to Participate in Upcoming Investor Conferences